LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within ...

AI investment is running hard, even with high interest rates, and that kind of capital hunger often spills into healthcare ...

Krystal Biotech Inc. KRYS on Thursday released a clinical update for its intratumoral immunotherapy, KB113. The treatment ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Legend Biotech Corporation ( LEGN) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for LB2501, an investigational in vivo CAR-T ...

The bulk of coverage towards the top gaining stock sectors over the past year has focused understandably on technology, which has made huge strides, with semiconductors exceeding +60%. However, the ...

After strong gains last year, biotech stocks are underperforming YTD despite a record wave of M&A activity fueled in part by leading drugmakers hunting for deals amid looming patent cliffs for their ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. I ...

Forbes contributors publish independent expert analyses and insights. Ray Fernandez is a Buenos Aires-based tech journalist. This voice experience is generated by AI. Learn more. This voice experience ...

Biotech firms are gaining major traction in 2026 due to the global pandemic. Take a look at some of the key features of ...